CJC-1295 is a modified fragment of growth hormone-releasing hormone. Two distinct things are sold under the name and they are not interchangeable.

CJC-1295 with DAC carries a Drug Affinity Complex that binds serum albumin, extending its half-life from minutes to something on the order of a week. CJC-1295 without DAC, properly modified GRF (1-29), has a half-life measured in minutes.

Those are different drugs with different exposure profiles and different plausible risk profiles, and treating a citation about one as evidence about the other is a category error that shows up in almost every discussion of it.

Both versions bind the GHRH receptor on pituitary somatotrophs and stimulate endogenous growth hormone release, preserving pituitary feedback in a way exogenous GH does not.

The DAC modification changes the pharmacology fundamentally rather than incrementally: sustained receptor exposure produces a raised GH and IGF-1 baseline rather than an amplified pulse. Since GH signalling is normally pulsatile and downstream effects are partly pattern-dependent, a sustained elevation is not simply "more of the same".

Early clinical pharmacokinetics only. There is no adequately powered efficacy trial for any clinical outcome.

The published human work establishes that it raises GH and IGF-1 in a dose-dependent, sustained way. The DAC version producing elevations lasting days. That is a pharmacodynamic result, not a clinical one.

For body composition, recovery, sleep quality, injury healing, or anything else discussed in community settings, there is no controlled human evidence. The reasoning chain, raises GH, therefore raises IGF-1, therefore produces outcome X, skips the step that pharmacology exists to test.

Human exposure is limited to small short-duration studies. Reported effects include injection site reactions, flushing, and headache.

The mechanistic concerns are those of sustained GH/IGF-1 elevation: insulin resistance and impaired glucose tolerance, fluid retention, arthralgia, and the mitogenic implications of chronic IGF-1 elevation. The DAC version's sustained profile makes these more relevant, not less, and no long-term data exists for it.

An additional practical issue specific to this compound: because both versions are sold under one name, buyers frequently do not know which molecule they have.

Never approved anywhere. Sold as a research chemical. Prohibited in sport under WADA's S2 category. Not manufactured to pharmaceutical standards outside a research setting.